Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000036648
JPRN-UMIN000036648
Completed
N/A

Mortality and risk factors for cardiovascular and non-cardiovascular disease in Japanese with impaired glucose metabolism - The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases (Hiroshima GMCVD)

Hiroshima Atomic Bomb Casualty Council0 sites19,248 target enrollmentMay 7, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Hiroshima Atomic Bomb Casualty Council
Enrollment
19248
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 7, 2019
End Date
April 30, 2019
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hiroshima Atomic Bomb Casualty Council

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Participants were on treatment for type 1 or type 2 diabetes.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
Risk factors for mortality and cardiovascular diseases in older adults in a primaray care setting – longitudinal analysis of the getABI-studyRisk factors for mortality and cardiovascular diseasesI70.20
DRKS00011624Ruhr-Universität Bochum6,880
Active, Not Recruiting
Phase 1
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 16.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2012-003946-34-CZVIVUS, Inc.16,000
Active, Not Recruiting
Phase 1
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 14.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2012-003946-34-SKVIVUS, Inc.16,000
Active, Not Recruiting
N/A
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 16.0Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2012-003946-34-GBVIVUS, Inc.16,000
Active, Not Recruiting
N/A
Mortality among dialysis patients prescribed sevelamer hydrochloride and lanthanum carbonate compared with calcium-based phosphate binders: A retrospective cohort study using the Australian and New Zealand Dialysis and Transplant Database (ANZDATA).
ACTRN12613000762752A/Prof Grahame Elder15,000